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Background: Spondylolisthesis is the major cause of refractory low back pain. There are many studies of the
surgical treatment of spondylolisthesis, but few of conservative treatments. There is also no optimal conservative
treatment protocol, however, low back pain caused by low-grade spondylolisthesis is controlled with non-surgical
pain management. Acupuncture has become a useful method for treating low back pain, but there has not been
any study of its efficacy in relation to spondylolisthesis. This study was designed to establish the feasibility of a
randomized controlled trial and the safety of acupuncture for low back pain due to low-grade spondylolisthesis.
Methods/Design: The study is a randomized controlled pilot clinical trial of five weeks duration. Fourteen patients
will be recruited and randomly allocated to two groups: an acupuncture plus interlaminar epidural steroid injection
group (experimental group), and an interlaminar epidural steroid injection group (control group). All patients will be
administered an interlaminar epidural steroid injection once a week for three weeks (three injections in total), but
only the experimental group will receive additional treatment with three acupuncture sessions a week for three
weeks (nine acupuncture sessions in total). The primary outcome will be measured by the visual analogue scale
(VAS). Our primary end point is three-week VAS. The secondary outcome will be measured using the PainVision
system, the short-form McGill Pain Questionnaire, and the Oswestry Disability Index. Assessments will be made at
baseline and at one, three and five weeks thereafter (that is, the five-week assessment will be made two weeks
after treatment cessation).
Discussion: This randomized controlled pilot trial will inform the design of a further full-scale trial. The outcomes
will provide some resources for incorporating acupuncture into existing pain management methods such as
interlaminar epidural steroid injection in low-grade spondylolisthesis.
Trial registration: This trial is registered with the US National Institutes of Health Clinical Trials registry:
NCT01909284.
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Spondylolisthesis is defined as anterior migration, or
slippage, of a vertebral body relative to the next caudad
vertebral segment [1]. Spondylosis and spondylolisthesis
occur most commonly in the fifth lumbar vertebral
body, but may occur at more cephalad lumbar levels. Pa-
tients with L4 spondylosis and spondylolisthesis are
more frequently symptomatic [2,3]. The symptoms clin-
ically associated with spondylolisthesis are low back pain
and pain, numbness, or weakness in the legs or lower
extremities [4]. The classification systems of Wiltse-
Newman [1] and Marchetti and Bartolozzi [5] are the
most widely used. In terms of describing the actual se-
verity of spondylolisthesis, the Meyerding scale is the
most widely recognized method. The magnitude of
spondylolisthesis is measured by dividing the slip dis-
tance by the caudad body width and expressed as a
percentage. The slip percentage is then categorized ac-
cording to the Meyerding scale as follows: Grade 0, no
slip; Grade I, 1 to 25%; Grade II, 26 to 50%; Grade III,
51 to 75%; Grade IV, 76 to 100%; Grade V: complete
slippage. Both the slip percentage and Meyerding grade
are reliable measures of severity [6,7].
Many patients with low-grade spondylolisthesis
(Meyerding grade 0, I, II) can be treated conservatively
[8]. Most patients with spondylolisthesis do not worsen
with time and rapid deterioration is very rare [9]. Phys-
ical therapy and pain management are the mainstays of
conservative treatment, and should be the initial course
of action in most cases of spondylolisthesis, with or
without neurological symptoms [8]. Most physicians
begin with antiinflammatory medications and physical
therapy, including aerobic conditioning, provided there
are no gastrointestinal contraindications. If symptoms
persist beyond four to six weeks, patients may benefit in
the short term from a course of epidural steroid injec-
tions. Benefits may include reduced lower back and
radiculopathy-associated pain [4,10].
Acupuncture has become a popular alternative treat-
ment modality for patients with low back pain, which is
the major symptom of spondylolisthesis. Indeed, acu-
puncture has been shown to be effective in relieving low
back pain [11,12]. Leibing et al. [13], Haake et al. [14],
and Brinkhaus et al. [15] all reported a significant differ-
ence in their primary outcome measures–Visual Analog
scale (VAS), Roland Morris Disability Questionnaire,
and McGill Pain Index. Witt et al. [16] also reported a
significant improvement in pain, function, and quality of
life after acupuncture treatment when compared to rou-
tine care, at three months. However, no published trials
have evaluated the efficacy and safety of acupuncture in
patients with low back pain due to spondylolisthesis.
In the evaluation of the clinical and radiographic result of
the transforaminal lumbar interbody fusion in degenerativeand isthmic lower-grade spondylolisthesis, there were 7.6%
serious postoperative complications observed, which re-
quired operative revision [17]. Acupuncture would be help-
ful in patients with spondylolisthesis as a safe conservative
treatment without severe adverse events as can happen in
some surgical procedures, such as transforaminal lumbar
interbody fusion. The primary aim of this trial is to estab-
lish the feasibility of a randomized controlled trial and the
safety of acupuncture for reducing low back pain due to
low-grade spondylolisthesis and improving function com-
pared with usual interlaminar epidural steroid injection.
Hypotheses
In this randomized controlled two-arm clinical trial, we
will evaluate the effect of acupuncture as an adjunct
therapy to spondylolisthesis. The primary hypothesis is
that acupuncture treatment in addition to interlaminar
epidural steroid injection reduces pain (as measured
by VAS) significantly more than interlaminar epidural
steroid injection only. The secondary hypotheses are
that: the score of the PainVision system (PS-2100, Nipro
Corporation, Osaka, Japan), is significantly lower in the
experimental group than that in the control group;
additional acupuncture treatment reduces the score on
the short-form McGill Pain Questionnaire (SF-MPQ)
significantly more than interlaminar epidural steroid in-
jection alone; interlaminar epidural steroid injection
combined with acupuncture is significantly better than
interlaminar epidural steroid injection alone in reducing
the score on the Oswestry Disability Index (ODI).
Methods/Design
Design
The study is a randomized controlled pilot clinical trial.
It is designed to assess the efficacy and safety of acu-
puncture treatment in patients with low back pain due
to low-grade spondylolisthesis. The protocols used ad-
here to the principles of the Declaration of Helsinki and
have been approved by the institutional review board
of Daegu Catholic University Hospital (IORG0004453),
where the study will take place. The trial is registered
with the US National Institutes of Health Clinical Trials
registry. Written consent will be obtained from each par-
ticipant before any treatment is given.
The outcome assessment and statistical analyses will
be performed by professionals blinded to the assignment
of patients. The trial process is presented in Figure 1.
The trial will run for five weeks. Patients will be allo-
cated to two groups; the control group will only receive
three interlaminar epidural steroid injections and the ex-
perimental group will receive all three steroid injections
as well as nine acupuncture sessions (three sessions a
week forthree weeks). Assessments will be made at base-
line, and again at one, three and five weeks thereafter.




: 3 sessions per week for 3 
weeks 
interlaminar epidural steroid 
injections
: once per week for 3 weeks
Control group (n=7)
interlaminar epidural steroid 
injections
: once per week for 3 weeks
Provide treatments over three weeks
Assess outcomes at baseline, and at 1, 3, and 5 weeks 
Figure 1 A flow chart of the trial process.
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after treatment cessation.
Recruitment
Participants will be recruited through advertisements on
hospital websites and bulletin boards. If patients are in-
terested in participation, they will be invited to visit the
hospital for a screening meeting. Their eligibility will be
determined by an anesthesiologist through physical and
radiological examinations. If eligible, they will be guided
through the informed consent process. After written
consent is obtained, a study researcher will randomly al-
locate the participants to one of the two groups. Treat-
ments will be scheduled after randomization.
Participants
One of the main objectives of this study is to provide an
estimate of the sample size required for the full-scale
randomized controlled clinical trial. We plan to recruit
14 patients into this pilot study. A target of 14 patients
with spondylolisthesis has been set.
The inclusion criteria are that participants must: be
aged 18 to 65 years, have Meyerding Grade I to IIspondylolisthesis, have low back pain of at least one-year
duration, be available for possible follow-up during the
clinical trial, and provide written informed consent
voluntarily.
The exclusion criteria are: cauda equina syndrome,
persistently exacerbated symptoms, progressive neuro-
logic signs (sensory or motor changes); previous spine
surgery; senile dementia, impaired cognitive function or
other cerebral disease, severe psychiatric or psychological
disorders; severe, concomitant disease (neuromuscular
scoliosis, neurodegenerative disease); all contraindications
to corticosteroid injection (e.g., insulin-dependent dia-
betes); alcohol/drug abuse; significant renal or hepatic
disease; pregnant, lactating or planning a pregnancy;
hypersensitive reaction to acupuncture treatment; inability
to comprehend or express oneself in the Korean language;
an individual deemed to be ineligible by a physician; or re-
fusal to participate in the trial or to provide informed
consent.
Randomization
Patients will be randomized using a computerized ran-
dom number generator by an independent statistician
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be performed once a participant is confirmed to be eli-
gible and their written informed consent has been
obtained.
Interventions
Patients will be randomly divided into two treatment
groups: an experimental group (acupuncture plus inter-
laminar epidural steroid injection group) and a control
group (interlaminar epidural steroid injection group).
The interlaminar epidural steroid injections will be ad-
ministered once per week for three weeks (three times
in total) and the acupuncture sessions performed three
times per week for three weeks (nine times in total).
Interlaminar epidural steroid injection
The lumbar interlaminar epidural injections will be ad-
ministered by an anesthesiologist under fluoroscopy in a
sterile procedure room in an outpatient pain manage-
ment department. The lumbar interlaminar epidural
space will be identified by the loss of resistance tech-
nique and by fluoroscopic visualization with confirm-
ation with a non-ionic contrast medium. The epidural
space will be entered at the level of spondylolisthesis or
one space above/below the level of spondylolisthesis.
After confirmation of needle placement, 10 mL mepiva-
caine hydrochloride 0.1% (preservative free) and 5 mg
non-particulate dexamethasone will be administered by
injection.
Acupuncture treatment
The following acupoints will be used: GV3 (unilateral),
BL23, BL24, BL25, GB30, GB31, BL40, and BL60 (bilat-
eral). In total, 15 acupoints will be used. Sterilized dis-
posable acupuncture needles (DongBang Acupuncture
Inc., Sungnam, Korea) 0.25 mm × 40 mm in size will be
manually inserted into each of the 15 acupoints. After
needle insertion, the Deqi sensation will be induced by
manual stimulation, and four acupoints (bilateral BL23,








Treatments Interlaminar epidural steroid injection
acupuncture √
ODI, Oswestry Disability Index; SF-MPQ, short-form McGill Pain Questionnaire; VAS, vdevice (ES-160, Ito Co. Ltd., Tokyo, Japan). The needles
will be inserted for 20 ± 5 minutes and then removed.
Data collection
In this study, the primary outcome will be measured by
VAS. The secondary outcome will be measured by the
PainVision system, the SF-MPQ and ODI. Both the pri-
mary and secondary outcomes will be measured at base-
line, and at one, three and five weeks thereafter. The
schedule of treatment and outcome assessments is pre-
sented in Table 1.
Primary outcome measurement
VAS
Pain intensity will be assessed using a10 cm VAS of sub-
jective pain assessment. Each patient will rate their pain
on a scale of 0 to 10 (0 being an absence of pain and 10
being the worst pain imaginable) [18,19]. VAS measure-
ments will be made at baseline, and at one, three and
five weeks. Our primary end point is three-week VAS.
Secondary outcome measurements
PainVision
PainVision is a system used for the quantitative analysis
of perception and pain; it has recently been introduced
in the field of pain and anesthesiology [20,21]. The Pain-
Vision system consists of four devices: (1) the main
PainVision system unit, (2) a personal computer con-
nected to the PainVision system, (3) sensors, and (4) a
printer. The specific protocols for using the systems are
as follows [22]: first, sensors that transmit an electric
current will be attached to the right medial forearm. The
current perception threshold that indicates the pain
threshold of each subject will be measured three times,
and the mean values will be used for analysis; Second,
the pain compatible electrical current will be measured
by a gradually increasing pulsed current applied to the
right medial forearm. The pain due to spondylolisthesis
and the magnitude of electric stimulation are believed
equal. The pain-compatible electrical current will be
measured three times, and the mean values will be usedghout the trial
Treatment period Follow-up period







√ √ √ √ √ √ √ √
isual analogue scale.
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intensity will be calculated using the following equation:




The SF-MPQ, a shorter version of the MPQ, is a multi-
dimensional measure of perceived pain in adults with
chronic pain [23,24]. The main component of the SF-
MPQ consists of 15 descriptors (11 sensory, 4 affective)
from the original MPQ. The descriptors are rated on an
intensity scale as 0 = none, 1 =mild, 2 =moderate, or
3 = severe. The SF-MPQ also includes the Present Pain
Intensity (PPI) scale. The PPI scale is a measure of the
magnitude of pain experienced by an individual and
a numeric-verbal combination that indicates overall
pain intensity and includes 6 levels: 0 = none, 1 = mild,
2 = discomforting, 3 = distressing, 4 = horrible, and 5 =
excruciating [25]. Higher numbers indicate more severe
pain. The SF-MPQ will be measured at baseline and at
one, three and five weeks.
ODI
The ODI is one of the most frequently used tools for
measuring disability related to low back pain [26]. The
ODI contains 10 questions about daily activities, includ-
ing inventories of pain intensity, personal care, lifting,
walking, sitting, standing, sleeping, sexual life, social life,
and traveling. Each question is rated on a scale from 0
to 5 points. The ODI scores range from 0 to 50. Higher
scores indicate greater disability. The validated Korean
version of the ODI [27] will be measured at baseline,
and at one, three and five weeks.
Safety
We will confirm the safety of acupuncture by determin-
ing the red blood cell (RBC) count, hemoglobin level,
platelet count, mean corpuscular volume (MCV), mean cor-
puscular hemoglobin (MCH), mean corpuscular hemoglobin
concentration (MCHC), hematocrit (Hct), total white blood
cell (WBC) count, erythrocyte sedimentation rate (ESR),
aspartate aminotransferase (AST), alanine aminotransfer-
ase (ALT), serum urea nitrogen (BUN), creatinine level,
serum sodium level, serum potassium level, and serum
chloride level. All patients were evaluated two times, in-
cluding the screening visit and after the termination of
acupuncture.
Any reported adverse events will be recorded through-
out the study and vital signs will be monitored at each
visit. The patients will be requested to voluntarily report
information about adverse events, and the researcher
will confirm the occurrence of adverse events throughmethods such as a medical interview. Details about ad-
verse events, such as the date of occurrence, degree of
adverse events, causal relationship with the treatment,
other treatments or medications that are suspected to
cause the adverse event, and treatment of the adverse
event, will be recorded in detail.
Withdrawal and dropout
All patients will have the right to withdraw from the
study at any time. Participation will be ended at any
stage if the patient refuses to continue, withdraws their
consent, or violates the inclusion or exclusion criteria or
the trial protocol. The trial will be stopped if the princi-
pal investigator believes that there are unacceptable risks
of serious adverse events.
Statistical analysis
The statistical significance level will be set at 5%, and
the data will be analyzed using intention-to-treat and
per protocol approaches. Data will be processed with
the last observation carried forward method for the
intention-to-treat analysis, and will be performed using
IBM SPSS Win ver. 19.0 statistical software (IBM Co.,
Armonk, NY, USA).
All demographic and clinical characteristics of the sub-
jects (such as sex, age, and weight) will be processed
based on descriptive analyses. Quantitative data will be
presented as average, standard deviation, median value,
and range. Qualitative data will be presented as the
frequency and percentage. The study will identify the
comparative equivalence of demographic variables and
clinical characteristics between the experimental and
control groups.
In order to identify differences in VAS, PainVision
scores, SF-MPQ and ODI scores between the experi-
mental and control group based on time (baseline, weeks
one, three and five), a repeated-measure twofactor ana-
lysis will be performed to identify differences between
groups, differences within each group based on time,
and the effects of the interaction of the variables based
on group. If the interaction between group and time is
statistically significant, the point at which the pattern of
results between the two groups changes will be checked.
The Chi-square test will be used to compare groups
and the incidence frequency of adverse events related to
acupuncture and interlaminar epidural steroid injection.
Discussion
Recently, there has been increased interest in the use of
acupuncture for treating diseases [28]. Many studies
have reported that acupuncture is suitable for providing
pain relief and improving function in patients with low
back pain [29]. However, there is currently no evidence
supporting the use of acupuncture in patients with low
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study will evaluate the feasibility of further research on
acupuncture as an effective and safe treatment for redu-
cing pain and improving function in these patients. Al-
though many surgical options exist for the treatment of
spondylolisthesis, it is generally agreed that in most
cases, conservative treatment should be attempted be-
fore surgical intervention.
Many clinical trials have compared surgical treatment
methods. However, no randomized clinical trial has
established an optimal non-operative treatment protocol
[4]. Our study is related to low-grade spondylolisthesis
to apply conservative treatment at first. This randomized
controlled pilot trial will inform the design of a further
full-scale trial. The outcomes will provide some re-
sources for incorporating acupuncture into existing pain
management programs such as interlaminar epidural
steroid injection for treating low-grade spondylolisthesis.
Trial status
This trial is currently recruiting participants. Enrollment
and trial completion is expected to be finished by the
end of 2013.
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